VanEck Biotech ETF (NASDAQ:BBH) Sees Large Increase in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,900 shares, an increase of 107.1% from the January 15th total of 1,400 shares. Based on an average trading volume of 11,600 shares, the days-to-cover ratio is currently 0.3 days.

VanEck Biotech ETF Stock Down 0.7 %

Shares of NASDAQ:BBH opened at $160.56 on Friday. The company has a 50 day moving average price of $161.38 and a two-hundred day moving average price of $169.95. VanEck Biotech ETF has a 52 week low of $151.35 and a 52 week high of $183.64.

VanEck Biotech ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were issued a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

Hedge Funds Weigh In On VanEck Biotech ETF

Institutional investors and hedge funds have recently modified their holdings of the business. International Assets Investment Management LLC raised its position in VanEck Biotech ETF by 10,376,390.9% in the 3rd quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock valued at $202,475,000 after buying an additional 1,141,403 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in VanEck Biotech ETF during the 4th quarter worth approximately $9,966,000. Strategic Financial Concepts LLC bought a new stake in shares of VanEck Biotech ETF in the fourth quarter worth $3,828,000. Raymond James Financial Inc. acquired a new position in VanEck Biotech ETF during the fourth quarter worth $3,381,000. Finally, Jane Street Group LLC grew its position in VanEck Biotech ETF by 401.7% in the third quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock valued at $1,481,000 after purchasing an additional 6,684 shares in the last quarter. 32.05% of the stock is currently owned by institutional investors and hedge funds.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.